Unidad Médica Onco-hematológica
Welcome,         Profile    Billing    Logout  
 22 Trials 
43 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fuxius, Stefan
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
LUSPLUS, NCT05181592 / 2020-004899-18: Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

Recruiting
3
70
Europe
Luspatercept, Reblozyl
GWT-TUD GmbH, Celgene
Myelodysplastic Syndromes
12/24
06/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Completed
N/A
499
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23
Eichbaum, Michael
MAMOC, NCT04227522: Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

Completed
3
42
Europe
Rucaparib, Placebos
North Eastern German Society of Gynaecological Oncology, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Clovis Oncology, Inc.
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Clear Cell Carcinoma
12/23
07/24
MATAO, NCT04111978 / 2019-002264-27: MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer

Recruiting
3
540
Europe
Letrozole 2.5mg, Femara, Placebo
Swiss GO Trial Group, AGO Study Group, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Reliable Cancer Therapies, Krebsliga Schweiz, Stiftung Guido Feger, Hoffmann-La Roche, Helsana AG, Novartis Pharmaceuticals, Anticancer Fund, Belgium
Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma
10/25
10/30
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Fasching, Peter
NeoON, NCT05036005: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label

Recruiting
4
108
Europe
Ontruzant, SB3, Chemotherapy, Pertuzumab
Institut fuer Frauengesundheit, Samsung Bioepis Co., Ltd.
Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer
04/23
07/23
AIRE, NCT05033769: Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer

Recruiting
4
82
Europe
Eribulin Injection [Halaven], Eribulin, Paclitaxel injection, Paclitaxel
Institut fuer Frauengesundheit, Eisai GmbH
Breast Cancer Female, Neoplasm, Breast, Breast Cancer Metastatic
07/23
09/23
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

Recruiting
4
1000
Europe
Ribociclib
Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals
Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer
10/24
10/26
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruiting
3
1684
Europe
Ribociclib 200Mg Oral Tablet, Kisqali
West German Study Group, Novartis, Genomic Health®, Inc.
Breast Cancer Female
07/27
07/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
COMPRENDO, NCT05033756: Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (

Active, not recruiting
2
11
Europe
Pembrolizumab Injection [Keytruda], Keytruda, Olaparib Oral Tablet [Lynparza], Lynparza
Institut fuer Frauengesundheit, Merck Sharp & Dohme LLC
Malignant Neoplasm of Breast, Breast Cancer
01/25
02/26
KEYNOTE 721, NCT03310957 / 2017-002289-35: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Completed
1/2
186
Europe, US, RoW
ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
09/24
09/24
CLEAR-B, NCT05870813: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer

Recruiting
N/A
3000
Europe
Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals
Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma
12/23
12/23
PRO2, NCT05425550: Evaluation of the Medidux™ Digital Health Application in Patients with HER2-positive Breast Cancer During Chemotherapy in Combination with HER2-targeted Therapy or Antibody-drug Conjugate Therapy.

Recruiting
N/A
585
Europe
medidux™ app
Palleos Healthcare GmbH, Mobile Health AG
Breast Cancer
09/25
09/25
NCT04755829: Breath Test to Predict Breast Cancer and Outcome of Mammography

Not yet recruiting
N/A
1000
Europe
BreathX test for breath VOCs
Menssana Research, Inc., Mount Vernon Cancer Centre, Zuyderland Medical Centre, University of Erlangen-Nürnberg
Breast Cancer, Abnormal Mammogram, Unspecified
03/23
03/23
Schenker, Michael
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Recruiting
3
1000
Europe, Canada, Japan, RoW
Dostarlimab, Belrestotug, Pembrolizumab, Placebo
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
09/28
09/29
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
560
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
ENGOT en-21, NCT05797831: Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Recruiting
2/3
268
Europe, Canada, US, RoW
Navtemadlin, KRT-232, Navtemadlin Placebo
Kartos Therapeutics, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Endometrial Cancer
08/25
07/27
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
498
Europe, RoW
SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate
Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
12/25
10/26
NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
Stahl, Nicole
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
GENERATE, NCT05867927: - Next GENERATion of GynEcological Surgery - Robotic Assisted Surgery in Gynecological Indications

Recruiting
N/A
1125
Europe
Robotic-assisted surgery (da Vinci), Non-da Vinci Surgery
Intuitive Surgical
GYN Disorders
03/27
06/27
Ditsch, Nina
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

Recruiting
4
1000
Europe
Ribociclib
Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals
Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer
10/24
10/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Bernal, Eduardo Tellez
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32

Download Options